Sensorion s’introduit sur Alternext Paris

Raises €8.2 million, market capitalisation totals €23 million

Paris – 21 April 2015–EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today congratulated Sensorion, a biotech company specialising in the treatment of pathologies of the inner ear, on its successful listing on Alternext in Paris.

Sensorion was spun off from Inserm, the French institute of health and medical research, in 2009 and is based in Montpellier in southern France. It focuses on all types of severe inner ear pathologies, affecting balance and hearing, and is developing three drug candidate programs for medical needs that remain untreated to date. The company has devised a full technology platform that allows it to identify and test the most promising drug candidates for all severe inner ear disorders, both symptomatic and anti-lesional. It plans to become a leading player in treating these pathologies.

Sensorion (ticker symbol: ALSEN) was listed through the admission to trading of 5,078,990 ordinary shares, including 1,816,100 new shares issued under a Global Offering[2].

The admission price and issue price of Sensorion was set at €4.54 per share. Market capitalisation on the day of listing was €23 million, and the operation raised a total of €8.2 million

Sensorion CEO Laurent Nguyen said: “We are delighted to list on Alternext in Paris. And we want to thank all of our shareholders—old and new—for helping us achieve this milestone and for accompanying us on the road to future growth. Thanks to their support and the hard work of our teams, we have every intention of rapidly becoming a major player in the treatment of inner ear pathologies.”

Eric Forest, Chairman and CEO of EnterNext, said “We are very pleased to welcome Sensorion, an innovative company from the Languedoc-Roussilon region, to Alternext. Listing should enable it to step up the pace of its product development. Today EnterNext is working with nearly 70 companies in the life sciences, representing total market capitalisation of over €11 billion. We believe that our initiatives in support of technology companies will strengthen our positioning in tech shares in Europe.”

_{[1]Small and medium-size companies

[2]TheGlobal Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries}

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.